12/4/2023 0 Comments Talos principle area 2Although DAPT reduces the risk of ischaemic events after ACS, it substantially increases the risk of bleeding 7, 8. The current ‘standard-of-care’ dual antiplatelet therapy (DAPT) for patients with ACS undergoing PCI, according to international guidelines, comprises aspirin combined with a potent P2Y purinoceptor 12 (P2Y 12) inhibitor, namely prasugrel or ticagrelor 1, 2, 3, 4, 5, 6. In this Consensus Statement, we summarize the evidence base for these treatment approaches, provide guidance on the assessment of ischaemic and bleeding risks, and provide consensus statements from an international panel of experts to help clinicians to optimize these DAPT approaches for individual patients to improve outcomes.Īntiplatelet therapy is central to the management of acute coronary syndromes (ACS) in patients undergoing percutaneous coronary intervention (PCI). However, these two strategies have not yet been compared in a head-to-head clinical trial. Abbreviation of DAPT duration after 1–6 months, followed by monotherapy with aspirin or a P2Y 12 inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk. De-escalation of DAPT intensity can reduce bleeding without increasing ischaemic events and can be guided by platelet function testing or genotyping. Either strategy requires assessment of the ischaemic and bleeding risks of each individual. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y 12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding. Lip ORCID: /0000-0002-7566-1626 29, 30, 31Ĭonventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y purinoceptor 12 (P2Y 12) inhibitor (prasugrel or ticagrelor) for 12 months. If you missed last night's stream or want a refresher, check out our round-up of everything announced in Sony's PlayStation Showcase.De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis More information on the game can be found on the official PlayStation blog. The Talos Principle 2 is set to release later this year on PC, PlayStation 5, and Xbox Series X/S. Needless to say, this is a game I'll be keeping an eye out for. The Talos Principle is one of the best puzzlers I've ever played, and its excellence is summed up well in our review of the game at launch by contributor Stace Harman. There'll also be multiple endings in The Talos Principle 2, as there were in the first game. Puzzle mechanics from the original such as directing lasers are back, with some new twists including gravity manipulation and mind transference. The player will be tasked with investigating a "mysterious megastructure", while also being presented with philosophical questions on "the nature of the cosmos, faith versus reason, and the fear of repeating humankind's mistakes". The sequel sees the android wake up in the real world, where humans have long been extinct. The story of The Talos Principle 2 picks up from where the original left off, where the player-character, an android, manages to demonstrate free will and intelligence and escapes the virtual world they were trapped in. The sequel was first announced in 2016, developer Alen Ladavac sneakily slipped the news in at the end of his talk at that year's Nordic Game conference. The Talos Principle first came out in 2014 on PC, and was followed up with DLC called Road to Gehenna and ports to Xbox One, PS4, Switch and mobile. An official reveal of The Talos Principle 2 was one of the many announcements during last night's PlayStation Showcase.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |